Ovation Fertility Announces New Private Equity Investor: Morgan Stanley Capital Partners

OrthoNext Digital Platform for the JuniOrtho Plating System Receives FDA Clearance

“Together, OrthoNext and the JuniOrtho Plating System provide a complete solution for surgeons looking for a plating system to address the specific demands of advanced deformity and trauma reconstruction of the lower extremities in the pediatric population,” said Orthofix President of Global Orthopedics Paul Gonsalves.

SonarMed, New Pediatric Monitor Alerts Clinicians To Potential Airway Obstructions During Ventilation Launched

"The SonarMed airway monitoring device has revolutionized the way we care for our littlest patients. There is no other device in the world that can tell you where the endotracheal tube is located within the airway continuously in real-time, and whether the tube is obstructed or even partially occluded," said Jamie W. Powers, M.D., MBA, neonatologist at Huntington Hospital in Pasadena, California.

Ovation® Fertility announced that it has partnered with a new private equity investor: investment funds managed by Morgan Stanley Capital Partners (MSCP), the middle-market-focused private equity team within Morgan Stanley Investment Management. The investment supersedes Ovation’s previous private equity partnership with WindRose Health Investors.

The current Ovation leadership team and base of physician shareholders will remain in place, allowing for continued growth under the same innovative business model that has revolutionized the fertility laboratory services business through increased collaboration and widespread implementation of evidence-based best practices. Ovation celebrated its four-year anniversary June 1, 2019, and since its founding, has more than doubled the size of the company across numerous metrics and helped thousands of people become parents through advanced reproductive science.

Ovation Fertility
Nate Snyder, CEO of Ovation Fertility

“I am delighted to announce that after extensive exploration and negotiation, Ovation has accomplished its goal of recapitalization in partnership with one of private equity’s most respected names,” said Nate Snyder, Ovation’s chief executive officer. “Morgan Stanley Capital Partners believes in our business model and appreciates the strong physician relationships we have developed. They are bringing to the executive team new ideas for growth that will propel us to achieve even better patient outcomes. I’m also grateful to our founding financial sponsor, WindRose Health Investors, who took a leap of faith on our vision to reduce the overall cost of having a family through more efficient and effective fertility care.”

“We are excited to invest in Ovation, which is a premier fertility services provider in the United States,” said Steve Rodgers, managing director of Morgan Stanley Capital Partners. “We believe Ovation represents a best-in-class management team who have partnered with industry-leading physician groups and highly attractive laboratories. We look forward to supporting our partner physicians during the coming years of growth, as they deliver the highest quality of care and execute our shared mission to serve individuals and couples across the United States and beyond.”



Subscribe to Medical Device News Magazine here.

Related Articles